Orphazyme A/S revised earnings guidance for the year 2021. For the year, the company expects net revenues to be in the range of DKK 35 million to DKK 37 million compared to previous guidance range of DKK 30 million to DKK 40 million. Operating loss to be in the range of DKK 630 million to DKK 640 million compared to previous guidance range of DKK 670 million to DKK 700 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
940 DKK | +1.79% |
|
-2.85% | -29.32% |
03-27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
1st Jan change | Capi. | |
---|---|---|
-29.32% | 4.82M | |
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.56B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |
- Stock Market
- Equities
- ORPHA Stock
- News Orphazyme A/S
- Orphazyme A/S Revises Earnings Guidance for the Year 2021